ALX Oncology Announces Oral Presentation at ASCO
ALX Oncology Holdings Inc. (NASDAQ: ALXO), renowned for its breakthrough therapies in cancer treatment, has recently stated that the updated results from its Phase 2 ASPEN-06 clinical trial are set to be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This event provides a platform for enlightening medical professionals and researchers about significant advancements aimed at enhancing patient outcomes.
Highlights of the ASPEN-06 Trial
The ASPEN-06 trial is a pivotal study investigating evorpacept, an innovative drug that blocks CD47, and is designed to work in conjunction with other treatments. This multi-center, randomized trial digs deep into the efficacy of evorpacept when combined with trastuzumab, CYRAMZA, and paclitaxel versus these traditional treatments used alone. Its focus is on patients diagnosed with HER2-positive gastric or gastroesophageal junction cancer who have previously undergone anti-HER2 therapies.
Presentation Details and Insights
During the symposium, the updated findings of the trial will be shared in an oral presentation scheduled as follows:
Title: Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC)
Presenter: Dr. Kohei Shitara, a prominent figure in gastrointestinal oncology.
Date and Time: Thursday, January 23, 2025, from 9:15 a.m. – 10:00 a.m. PST
Session: Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach
Location: Level 2 Ballroom
Significance of Evorpacept in Cancer Therapy
Evorpacept represents a new frontier in cancer treatment, engaging the body’s immune response to combat tumor cells effectively. It’s being investigated through several clinical trials that test its potential across a variety of cancer types. Many believe that the promising outcomes of the ASPEN-06 trial could position evorpacept as a cornerstone in future immuno-oncology strategies.
Future Directions for ALX Oncology
ALX Oncology is keen on continuously shaping the landscape of cancer therapies. The results from the ASPEN-06 trial could significantly impact the direction of treatment protocols, especially for patients suffering from challenging cancers like gastric cancer. The anticipation surrounding this presentation spotlights the company’s dedication to innovating patient care.
Company Overview and Core Values
As a trailblazer in the biotechnology sector, ALX Oncology (NASDAQ: ALXO) focuses on therapies that amplify the immune response in the fight against cancer. Their lead product candidate, evorpacept, aims to redefine treatment regimens, potentially extending and enhancing the quality of life for patients undergoing cancer therapies. Their ongoing commitment to research and development has positioned them as leaders in their field.
Frequently Asked Questions
What is ALX Oncology presenting at the ASCO symposium?
ALX Oncology will present updated results from the Phase 2 ASPEN-06 clinical trial, focusing on the efficacy of evorpacept in cancer treatment.
What is evorpacept?
Evorpacept is an investigational CD47-blocking therapeutic designed to enhance the immune system's ability to target and destroy cancer cells.
Who will present the findings at ASCO?
The findings will be presented by Dr. Kohei Shitara, a leading figure in gastrointestinal oncology.
How does the ASPEN-06 trial work?
It is a randomized trial assessing the efficacy of evorpacept combined with other treatments compared to those treatments alone in patients with HER2-positive gastric cancer.
When is the ASCO symposium taking place?
The symposium will occur from January 23 - 25, 2025, in San Francisco.
